Which varieties of high-value medical consumables are expected to enter the next round of national centralized procurement in an orderly manner

Pharmaceutical Network News on July 29.
A few days ago, the National Medical Insurance Administration, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Finance, the National Health Commission, the State Administration for Market Regulation, the State Food and Drug Administration, and the Central Military Commission’s Logistics Support Department jointly Issued the "Guiding Opinions on the Centralized Procurement and Use of High-value Medical Consumables by National Organizations" (hereinafter referred to as the "Guiding Opinions"), which aims to develop national organizations in six aspects, including overall requirements, coverage, procurement rules, and safeguards.
It is worthwhile to put forward relevant opinions on the centralized procurement and use of medical consumables
.
Through analysis, it can be seen that the "Guiding Opinions" follow the three basic ideas of national centralized procurement of pharmaceuticals : one is to follow the general idea of ​​national organization, alliance procurement, and platform operation; second, to ensure product quality as a guide for clinical needs; It is to insist on the integration of recruitment and procurement, and the linkage of volume and price
.
At the same time, the "Guiding Opinions" comprehensively considered the particularities of high-value medical consumables, and proposed that the formulation of a plan requires "strategies in accordance with their aptitude
.
" In addition, the "Guiding Opinions" also emphasized the guarantee of the supply of high-value medical consumables, and put forward the policy joint efforts formed by multiple departments to ensure the orderly progress of the procurement work, and guide the centralized procurement of high-value medical consumables from multiple aspects, levels and angles
.

National and local centralized procurement is gradually spreading.

According to the "Guiding Opinions", high-value medical consumables with large clinical usage, high purchase amount, mature clinical use, sufficient market competition, and high level of homogeneity are the focus of centralized procurement.
Objects, involving the fields of cardio-cerebrovascular, orthopedics and ophthalmology
.
Up to now, the state has carried out two collections of high-value medical consumables for products such as coronary stents and artificial joints
.
In addition to national centralized procurement, provincial and multi-provincial-city alliance centralized procurement has also become the "main force" of consumables centralized procurement
.
At the beginning of this year, Sichuan carried out the centralized procurement of coronary balloons in the "six provinces and two regions" inter-provincial alliance; Inner Mongolia led 13 provinces (regions) and the Xinjiang Production and Construction Corps to carry out the centralized procurement of artificial joints and coronary guide wires
.
At the end of February, Guangdong, together with Jiangxi and Henan, launched the nation’s first alliance of intraocular lens procurement this year.

.
According to data from the Guangdong Pharmaceutical Trade Center, based on the average price of the selected products, it is expected that Guangdong Central Procurement will save 355 million yuan in the purchase of intraocular lenses in the first year
.
In March, in order to meet the national centralized procurement of coronary stents, the Beijing-Tianjin-Hebei "3+N" alliance launched the centralized procurement of coronary balloons that belong to the field of coronary therapy
.
According to data from Hebei Medical Insurance Bureau, a total of 72 products from 31 companies were selected
.
The average product price dropped from 3,401 yuan to 319 yuan.
Compared with 2020, the average price of the same products of the same company was reduced by 90%, the average price of domestic products was reduced by 90.
72%, and the average price of imported products was reduced by 88.
97%
.
In June, Anhui asked for opinions on the collection of orthopedic spinal consumables and intraocular lenses
.
In the same month, the Shanghai Municipal Pharmaceutical Centralized Bidding and Purchasing Affairs Management Office announced the results of the selection of Shanghai coronary balloon medical consumables.
It showed that 53 products from 31 companies including Boston Scientific, Abbott, Minimally Invasive Medical, and Sino Medical were selected
.
In addition, the collection of high-value medical consumables such as coronary balloons and intraocular lenses is also underway in Jiangsu and Fujian
.
Among them, the Jiangsu Provincial Medical Insurance Bureau announced the results of the proposed selection in June
.
The results showed that a total of 33 intraocular lens products were proposed to be selected, involving 15 companies including Ophthalmia, Aibonod, and Xiangle Medical.
The average price drop of mainstream products was 38%, and the highest drop was 79%; coronary dilatation balloons had a total of 25 products are planned to be selected, involving 15 companies including Medtronic, Poco, Lepu Medical, and Yeju Medical.
The average price drop is 86%, and the highest drop is 94%
.

　　Coronary balloons and intraocular lenses have become popular.

At present, products such as intraocular lenses and coronary balloons have become hotspots for provincial and multi-provincial alliances.

.
In May 2020, the National Medical Insurance Administration issued a notice requiring provincial platforms to report the purchase prices and purchases of three categories of products: coronary stents, coronary balloons, and intraocular lenses in 2019
.
It can be predicted that two types of consumables, coronary balloon and intraocular lens, are expected to enter the next round of national collection of high-value medical consumables
.
Among them, intraocular lenses are regarded as the hottest variety in the next round of high-value medical consumables collected by countries
.
Public data shows that among all kinds of consumables, intraocular lenses have the highest coverage in centralized mining areas, with a national coverage of more than 70%
.
With reference to the centralized procurement process of coronary stents, if intraocular lenses are included in centralized procurement, the price drop is expected to exceed the average decline in regional centralized procurement
.
Judging from the data collected by the Guangdong, Jiangxi, and Henan intraocular lens alliances in February this year, the purchase amount of the soft single-focal lens, which accounts for 88.
5% of the total, has dropped from 2,878 yuan to 1,255 yuan per unit, with the highest drop of 77%.
, The lowest winning price is 229 yuan, and the winning bidders include Bausch & Lomb, Alcon and Aibo Nord
.
In other words, the national centralized procurement price of intraocular lenses is expected to drop to a hundred yuan level
.

　　Ensuring product quality and safety is the top priority.

"Price-for-quantity, linked to volume and price" is one of the methods of centralized procurement, but price reduction is not the only goal of centralized procurement.
Ensuring product quality is the top priority
.
The “Guiding Opinions” put the guarantee of product quality and safety in the first place, emphasized the need to scientifically and rigorously formulate the quality and technical standards for purchasing high-value medical consumables, and strengthen the quality and safety supervision of the entire chain of production, circulation, and use of selected products.
The selected product quality problem resolution mechanism, supervise and urge enterprises to implement the main responsibility
.
In addition, to ensure product quality and safety, the coordination and linkage of multiple departments such as medical insurance and drug supervision are required to "act in accordance with the characteristics of high-value medical consumables", flexibly formulate high-value medical consumables procurement rules, optimize the procurement model, and form a joint effort.
fist"
.
In the future, the implementation mechanism for centralized procurement of consumables is expected to achieve "one product, one policy".
Featured consumables in some segments are more flexible in terms of quantity and price selection, which is expected to usher in new changes and open new markets
.
In general, the centralized procurement of high-value medical consumables will bring a short period of pain to local enterprises, but it is also a policy opportunity
.
On the one hand, it provides domestic brands with the opportunity to compete with imported brands on the same stage; on the other hand, it also helps the bid-winning enterprises to increase the market scale of their products and expand their brand awareness
.
With the joint efforts of enterprises and government departments, domestic high-value medical consumables will better achieve price reduction and quality improvement
.